Table 3 dverse events in each cohort
Adverse events (%) | 4 courses (n = 99) | > 4 courses (n = 64) | ||
|---|---|---|---|---|
Grade1–2 | Grade3 | Grade1–2 | Grade3 | |
Overall | 37 (37.4) | 15 (15.2) | 25 (39.1) | 10 (15.6) |
Leukopenia | 18 (18.2) | 2 (2.0) | 10 (15.6) | 2 (3.1) |
Neutropenia | 23 (23.2) | 3 (3.0) | 11 (17.2) | 2 (3.1) |
Thrombocytopenia | 5 (5.1) | 1 (1.0) | 3 (4.7) | 2 (3.1) |
Anemia | 14 (14.1) | 0 (0) | 9 (14.1) | 1 (1.6) |
Elevated AST level | 9 (9.1) | 2 (2.0) | 6 (9.4) | 2 (3.1) |
Elevated ALT level | 7 (7.1) | 1 (1.0) | 4 (6.3) | 0 (0) |
Elevated total bilirubin level | 13 (13.1) | 1 (1.0) | 6 (9.4) | 1 (1.6) |
Oral mucositis | 7 (7.1) | 1 (1.0) | 3 (4.7) | 1 (1.6) |
Nausea/Vomiting | 14 (14.1) | 2 (2.0) | 7 (10.9) | 2 (3.1) |
Fatigue | 21 (21.2) | 1 (1.0) | 12 (18.8) | 1 (1.6) |
Diarrhea | 12 (12.1) | 1 (1.0) | 8 (12.5) | 2 (3.1) |